AcquisitionsApr 14, 2026, 08:11 PM
Mesoblast acquires CAR tech license from Mayo Clinic for cell therapies
AI Summary
Mesoblast Limited has acquired an exclusive worldwide license to a patented Chimeric Antigen Receptor (CAR) technology platform from Mayo Clinic. This technology aims to enhance the target specificity and potency of Mesoblast's mesenchymal lineage stromal cell (MSC) products for inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, and Lupus Nephritis. The acquisition was completed through the issuance of ASX ordinary shares, with Mayo Clinic also providing in-kind support.
Key Highlights
- Acquired exclusive worldwide license to CAR technology platform.
- Technology developed by Mayo Clinic to enhance MSC product effectiveness.
- Aims to boost potency for inflammatory and autoimmune diseases.
- Acquisition completed by issuing ASX ordinary shares.
- Mayo Clinic to provide in-kind support for technology advancement.